Management of patients with rheumatoid arthritis by telemedicine: connected monitoring. A randomized controlled trial - 21/09/22
Highlights |
• | Connected monitoring of RA patients reduces in-person visits and seems to improve patient health status. |
• | Connected monitoring is less expensive than conventional face-to-face monitoring. |
• | Connected monitoring of RA patients initiating DMARD treatment appears cost-effective. |
Abstract |
Objectives |
Rheumatoid arthritis (RA) is a prevalent and disabling disease that is the source of significant direct and indirect costs. The current recommended therapeutic strategy is based on the rapid introduction of therapy with conventional Disease-Modifying Anti-Rheumatic Drugs (DMARDs) combined with regular disease monitoring by the rheumatologist. The onerous nature of such intense monitoring has motivated the development of new, less demanding strategies such as telemedicine. This study aimed to estimate the cost-effectiveness of the connected monitoring of RA patients initiating a new DMARD therapy versus conventional monitoring.
Methods |
An economic evaluation based on a randomized controlled trial of 89 patients was conducted. The patients in the intervention group (n=45) were monitored using a connected monitoring interface on a smartphone, while patients in the control group (n=44) were conventionally monitored. Health outcomes were measured as the gain in quality-adjusted life-years (QALYs), assessed using the EuroQol-5D questionnaire. Resource use and health outcomes were collected alongside the trial and at the six-month follow-up using application data and the related clinical case manager time, visits, hospitalisations, and transport records. These outcomes were valued using externally collected data on unit costs and QALY weights.
Results |
Compared to conventionally monitored patients, patients receiving connected monitoring had a slightly greater but not significant gain in the average QALY of 0.07. The economic analysis found that connected monitoring resulted in a significant cost reduction of 72€ (2927€ vs. 2999€, P<0.01). The incremental cost-utility ratio of the intervention was equal to –1,029€ per QALY (95% CI: –32,033; +24,625) with a 97.8% chance of being cost-effective at a threshold of 30,000€ per QALY gained.
Conclusion |
Implementing EULAR recommendations for RA patients initiating a DMARD treatment using connected monitoring is more efficient and less expensive than conventional care.
Clinical trial registration number |
ClinicalTrials.gov (NCT03005925).
Le texte complet de cet article est disponible en PDF.Keywords : Rheumatoid arthritis, Telemedicine, Medico-economic study, Cost-effectiveness, QALY, Connected monitoring
Plan
Vol 89 - N° 5
Article 105368- octobre 2022 Retour au numéro
Article précédent
- Lifetime female hormonal exposure and risk of rheumatoid arthritis in postmenopausal women: Results from the French E3N cohort
- Carine Salliot, Yann Nguyen, Amandine Gelot, Xavier Mariette, Marie-Christine Boutron-Ruault, Raphaèle Seror
- Presence of spondyloarthritis associated to higher disease activity and HLA-B27 positivity in patients with early Crohn's disease: Clinical and MRI results from a prospective inception cohort
- Valeria Rios Rodriguez, Elena Sonnenberg, Fabian Proft, Mikhail Protopopov, Michael Schumann, Lea I. Kredel, Judith Rademacher, Murat Torgutalp, Hildrun Haibel, Maryna Verba, Britta Siegmund, Denis Poddubnyy
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?